Geneva, Feb. 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119085) titled 'A Single-Arm, Multicenter, Phase II Clinical Study Protocol of Sintilimab Combined with Anlotinib and TP Regimen Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma' on Feb. 14.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Mianyang Central Hospital
Condition:
Head and Neck Squamous Cell Carcinoma, HNSCC
Recruitment Status: Recruiting
Phase: 2
Date of First Enrollment: 2026-02-16
Target Sample Size: experimental group:25;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=302692
Disclaimer: Curated b...